167 related articles for article (PubMed ID: 15464424)
21. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar.
Spraggs C; McCarthy A; McCarthy L; Hong G; Hughes A; Lin X; Sathe G; Smart D; Traini C; Van Horn S; Warren L; Mosteller M
Pharmacogenet Genomics; 2007 Dec; 17(12):1065-76. PubMed ID: 18004211
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor gamma: the more the merrier?
Argmann CA; Cock TA; Auwerx J
Eur J Clin Invest; 2005 Feb; 35(2):82-92; discussion 80. PubMed ID: 15667578
[TBL] [Abstract][Full Text] [Related]
23. The effects of obesity-associated insulin resistance on mRNA expression of peroxisome proliferator-activated receptor-gamma target genes, in dogs.
Gayet C; Leray V; Saito M; Siliart B; Nguyen P
Br J Nutr; 2007 Sep; 98(3):497-503. PubMed ID: 17475082
[TBL] [Abstract][Full Text] [Related]
24. Interaction between PPARG Pro12Ala and ADIPOQ G276T concerning cholesterol levels in childhood obesity.
Johansson LE; Danielsson P; Norgren S; Marcus C; Ridderstråle M
Int J Pediatr Obes; 2009; 4(2):119-25. PubMed ID: 18645733
[TBL] [Abstract][Full Text] [Related]
25. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Geese WJ; Achanzar W; Rubin C; Hariharan N; Cheng P; Tomlinson L; Ordway N; Dracopoli NC; Delmonte T; Hui L; Krishnan B; Cosma G; Ranade K
Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study.
Doney AS; Fischer B; Leese G; Morris AD; Palmer CN
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2403-7. PubMed ID: 15486307
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes.
Stefanski A; Majkowska L; Ciechanowicz A; Frankow M; Safranow K; Parczewski M; Pilarska K
Arch Med Res; 2006 Aug; 37(6):736-43. PubMed ID: 16824933
[TBL] [Abstract][Full Text] [Related]
28. Energy balance and food intake: the role of PPARgamma gene polymorphisms.
Cecil JE; Watt P; Palmer CN; Hetherington M
Physiol Behav; 2006 Jun; 88(3):227-33. PubMed ID: 16777151
[TBL] [Abstract][Full Text] [Related]
29. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
30. [Mutations of peroxisome proliferator-activated receptor gamma (PPARgamma): clinical implications].
Gacka M; Adamiec R
Postepy Hig Med Dosw (Online); 2004; 58():483-9. PubMed ID: 15765009
[TBL] [Abstract][Full Text] [Related]
31. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
32. PPAR gamma as a metabolic regulator: insights from genomics and pharmacology.
Savage DB
Expert Rev Mol Med; 2005 Jan; 7(1):1-16. PubMed ID: 15673477
[TBL] [Abstract][Full Text] [Related]
33. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
Gacka M; Adamiec R; Dobosz T; Szymaniec S; Bednarska-Chabowska D
Przegl Lek; 2004; 61(12):1436-9. PubMed ID: 15850344
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
35. [Mutations of the lamin A/C gene causing familial partial lipodystrophy: significance for the development of hyperlipidemia and insulin resistant diabetes mellitus].
Genschel J; Lochs H; Schmidt HH
Z Gastroenterol; 2000 Apr; 38(4):341-3. PubMed ID: 10820868
[No Abstract] [Full Text] [Related]
36. [PPARgamma variants and complex diseases].
Ji SL; Huang QY
Yi Chuan; 2006 Aug; 28(8):993-1001. PubMed ID: 16870588
[TBL] [Abstract][Full Text] [Related]
37. [PPARG gene polymorphism and disease susceptibility].
Yasuda K
Nihon Rinsho; 2010 Feb; 68(2):194-200. PubMed ID: 20158084
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
[TBL] [Abstract][Full Text] [Related]
39. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
[TBL] [Abstract][Full Text] [Related]
40. Genetics and Clinical Characteristics of PPARγ Variant-Induced Diabetes in a Chinese Han Population.
Gong S; Han X; Li M; Cai X; Liu W; Luo Y; Zhang SM; Zhou L; Ma Y; Huang X; Li Y; Zhou X; Zhu Y; Wang Q; Chen L; Ren Q; Zhang P; Ji L
Front Endocrinol (Lausanne); 2021; 12():677130. PubMed ID: 34764936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
